Fidelity Investments’s BridgeBio Pharma BBIO Stock Holding History

Fidelity Investments’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$154M	Sell	2,061,307 -282,447	-12%	-$19.8M	0.01%	1044
2026 Q1	$174M	Sell	2,343,754 -46,608	-2%	-$3.38M	0.01%	929
2025 Q4	$183M	Buy	2,390,362 +689,615	+41%	+$45.3M	0.01%	906
2025 Q3	$88.3M	Sell	1,700,747 -326,648	-16%	-$15.9M	﹤0.01%	1239
2025 Q2	$87.5M	Sell	2,027,395 -148,404	-7%	-$5.4M	﹤0.01%	1174
2025 Q1	$75.2M	Buy	2,175,799 +554,204	+34%	+$18.7M	﹤0.01%	1202
2024 Q4	$44.5M	Sell	1,621,595 -198,727	-11%	-$5.14M	﹤0.01%	1428
2024 Q3	$46.3M	Buy	1,820,322 +280,409	+18%	+$7.36M	﹤0.01%	1412
2024 Q2	$39M	Sell	1,539,913 -785,699	-34%	-$21.5M	﹤0.01%	1405
2024 Q1	$71.9M	Sell	2,325,612 -88,729	-4%	-$3.02M	﹤0.01%	1188
2023 Q4	$97.5M	Sell	2,414,341 -13,181	-0.5%	-$396K	0.01%	1023
2023 Q3	$61M	Buy	2,427,522 +766,639	+46%	+$21.8M	0.01%	1187
2023 Q2	$28.6M	Sell	1,660,883 -443,351	-21%	-$6.67M	﹤0.01%	1489
2023 Q1	$34.9M	Buy	2,104,234 +1,401,129	+199%	+$16.3M	﹤0.01%	1387
2022 Q4	$5.36M	Sell	703,105 -280,244	-28%	-$2.68M	﹤0.01%	2096
2022 Q3	$9.77M	Buy	983,349 +2,987	+0.3%	+$31K	﹤0.01%	1907
2022 Q2	$8.9M	Buy	980,362 +3,165	+0.3%	+$26.5K	﹤0.01%	2018
2022 Q1	$9.92M	Sell	977,197 -204,839	-17%	-$2.1M	﹤0.01%	2124
2021 Q4	$19.7M	Sell	1,182,036 -506,114	-30%	-$21.4M	﹤0.01%	1831
2021 Q3	$79.1M	Buy	1,688,150 +301,462	+22%	+$16.2M	0.01%	1204
2021 Q2	$84.5M	Sell	1,386,688 -268,876	-16%	-$15.4M	0.01%	1196
2021 Q1	$102M	Buy	1,655,564 +244,293	+17%	+$16M	0.01%	1059
2020 Q4	$100M	Buy	1,411,271 +386,318	+38%	+$18.6M	0.01%	1028
2020 Q3	$38.5M	Sell	1,024,953 -523,943	-34%	-$16.5M	﹤0.01%	1295
2020 Q2	$50.5M	Sell	1,548,896 -78,356	-5%	-$2.39M	0.01%	1157
2020 Q1	$47.2M	Sell	1,627,252 -565,448	-26%	-$17.5M	0.01%	1059
2019 Q4	$76.9M	Sell	2,192,700 -444,438	-17%	-$12.3M	0.01%	1026
2019 Q3	$56.6M	Sell	2,637,138 -380,848	-13%	-$10.5M	0.01%	1112
2019 Q2	$81.4M	Buy	+3,017,986	New	+$82.3M	0.01%	1001

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Fidelity Investments's BBIO Position: Q2 2026 in Review

Fidelity Investments reduced its BridgeBio Pharma (BBIO) stake by 12% in Q2 2026, selling an estimated $19.8M and leaving 2,061,307 shares worth $154M. The position accounts for 0.01% of the portfolio, ranked #1044.

Fidelity Investments first reported a position in BBIO in Q2 2019 and has held it in 29 quarters since. The position peaked at $183M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Fidelity Investments held 2,061,307 shares of BridgeBio Pharma worth $154M as of Q2 2026.
Fidelity Investments sold 282,447 BridgeBio Pharma shares in Q2 2026, an estimated $19.8M.
BridgeBio Pharma made up 0.01% of Fidelity Investments's portfolio in Q2 2026, its #1044 holding.
Fidelity Investments first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 29 quarters since.
Fidelity Investments's BridgeBio Pharma position peaked at $183M in Q4 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.